OncoMatch/Clinical Trials/NCT05607498

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Is NCT05607498 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies EMB07 for advanced/metastatic solid tumors.

Phase 1RecruitingEpimAb Biotherapeutics (Suzhou)Co., Ltd.NCT05607498Data as of May 2026

Treatment: EMB07 — For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Non-Hodgkin Lymphoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: ror1-targeted therapy

Lab requirements

Blood counts

Kidney function

Liver function

Adequate organ function to participate in the trial.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify